Search

Your search keyword '"Ma, Zhiyong"' showing total 1,445 results

Search Constraints

Start Over You searched for: Author "Ma, Zhiyong" Remove constraint Author: "Ma, Zhiyong"
1,445 results on '"Ma, Zhiyong"'

Search Results

201. sj-docx-1-tam-10.1177_17588359221138380 – Supplemental material for An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)

203. Potential Role of Flavivirus NS2B-NS3 Proteases in Viral Pathogenesis and Anti-flavivirus Drug Discovery Employing Animal Cells and Models: A Review

208. Molecular Epidemic Characteristics and Genetic Evolution of Porcine Circovirus Type 2 (PCV2) in Swine Herds of Shanghai, China

210. An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)

215. Various mobile genetic elements carrying optrA in Enterococcus faecium and Enterococcus faecalis isolates from swine within the same farm.

216. A Class of Organic Units Featuring Matrix‐Controlled Color‐Tunable Ultralong Organic Room Temperature Phosphorescence.

225. A Novel Recombinant Virus-Like Particles Displaying B and T Cell Epitopes of Japanese Encephalitis Virus Offers Protective Immunity in Mice and Guinea Pigs

226. Codoped 2D All-Inorganic Halide Perovskite Cs3Cd2Cl7:Sb3+:Mn2+with Ultralong Afterglow

228. Recent progress in determination of ochratoxin a in foods by chromatographic and mass spectrometry methods.

231. Corrigendum to “A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients” [Lung Cancer 147 (2020) 259–268]

233. Abstract CT039: Results from RATIONALE 303: A global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC

240. Subtyping of type A influenza by sequencing the variable regions of HA gene specifically amplified with RT-PCR

244. Progression pattern and post-progression treatment of furmonertinib (AST2818) in EGFR T790M mutation positive NSCLC patients: A post-hoc analysis from a multicenter, single-arm study.

246. Comparison of population characteristics, treatment modes, and clinical outcomes of patients with advanced non-small cell lung cancer in clinical trials and in the real world received PD-1/PD-L1 inhibitor.

Catalog

Books, media, physical & digital resources